A Trans-Nordic Study of Extreme Major Depression

跨北欧的极度抑郁症研究

基本信息

  • 批准号:
    10376800
  • 负责人:
  • 金额:
    $ 79.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-06-10 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract Major depressive disorder (MDD) affects >300 million people worldwide. It is a leading contributor to disability and suicide, and thus a cross-cutting risk factor for many adverse life and health outcomes. It is heritable, and genome-wide association recently been informative. However, nearly all current MDD samples are not enriched in individuals with the highest clinical severity (i.e., the extreme tail of the phenotype distribution), a critical weakness for clinical prediction. We propose to focus on “phenotype extreme MDD”. We will define these individuals empirically on a population scale over years of follow-up in order to capture individuals with markedly worse MDD clinical features (e.g., treatment-resistance, dense patterns of treatment, psychosis) and poor outcomes (e.g., poor social function, disability, suicide). Cases with phenotype extreme MDD disproportionally contribute to the global burden of MDD. We show that we can identify these individuals and preliminary data suggest these individuals have a greater inherited burden of MDD risk alleles. We will address an additional weakness in the field via multiple, highly powered layers of replication in independent cohorts. We need to know quickly whether a promising model can replicate and generalize, and we have built the infrastructure for this. In Aim 1, we will empirically identify “phenotype extreme MDD” in a training set of ⅓ of the Swedish population with replication in independent samples (the other ⅔ from Sweden and harmonized datasets from Denmark and Norway) and then generalization to independent samples from the UK (Generation Scotland, UK Biobank), and the US (PsycheMERGE). In Aim 2, we will validate the empirical phenotype extreme MDD definition using genomic data in the Aim 1 populations (i.e., pedigree- and SNP-heritability, contrast with other MDD definitions, evaluate whether individuals with phenotype extreme MDD carry higher genetic risk scores for MDD). In Aim 3, we will develop clinically useful prediction algorithms for extreme MDD: can we predict at first presentation who will subsequently develop phenotype extreme MDD? We will have exceptional statistical power for all Aims. Successful completion of these aims will enable our transformative, tertiary-preventive intention of valid and clinically useful prediction of the subsequent development of phenotype extreme MDD early in a person’s treatment history. This is foundational to achieve the overarching translational goal of deploying these models on national scales in order to improve the health of MDD patients who are most severely ill.
项目总结/摘要 重度抑郁症(MDD)影响着全世界超过3亿人。它是导致残疾的主要因素 和自杀,因此是许多不良生活和健康结果的交叉风险因素。它是可遗传的, 全基因组关联最近提供了信息。然而,几乎所有当前MDD样品都没有富集 在具有最高临床严重性的个体中(即,表型分布的极端尾部),一个关键的 临床预测的弱点。我们建议关注“表型极端MDD”。我们将定义这些 在多年的随访中,在人群规模上经验性地对个体进行研究,以捕获具有显著 更差的MDD临床特征(例如,治疗抵抗,密集的治疗模式,精神病)和穷人 结果(例如,社会功能差、残疾、自杀)。表型极端MDD的病例 导致MDD的全球负担。我们证明我们可以识别这些个体和初步数据 提示这些个体具有更大的MDD风险等位基因遗传负担。我们将讨论一个额外的 通过在独立的队列中进行多个高功率复制层来消除该领域的弱点。我们需要知道 快速判断一个有前途的模型是否可以复制和推广,我们已经为此建立了基础设施。 在目标1中,我们将在瑞典人群的伪样本训练集中凭经验识别“表型极端MDD”。 在独立样本中重复(另一个来自瑞典的数据集和来自丹麦的协调数据集, 挪威),然后推广到来自英国的独立样本(苏格兰一代,英国生物银行),以及 美国(PsycheMERGE)在目标2中,我们将验证经验表型极端MDD定义, Aim 1群体中的基因组数据(即,与其他MDD定义相比, 评估具有极端MDD表型的个体是否携带MDD的更高遗传风险分数)。在目标3中, 我们将为极端MDD开发临床上有用的预测算法:我们能否在第一次介绍时预测谁 会发展成极端的MDD表型吗我们将有特殊的统计能力为所有的目标。 成功地完成这些目标将使我们的变革性、第三预防性意图有效, 临床上有用的预测表型极端MDD的后续发展早期在一个人的 治疗史这是实现部署这些模型的总体转换目标的基础 在全国范围内,以改善病情最严重的MDD患者的健康。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PATRICK F SULLIVAN其他文献

PATRICK F SULLIVAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PATRICK F SULLIVAN', 18)}}的其他基金

1/3 Sequencing and Trans-Diagnostic Phenotyping of Severe Mental Illness in Diverse Populations
不同人群中严重精神疾病的 1/3 测序和跨诊断表型
  • 批准号:
    10502677
  • 财政年份:
    2022
  • 资助金额:
    $ 79.52万
  • 项目类别:
A Trans-Nordic Study of Extreme Major Depression
跨北欧的极度抑郁症研究
  • 批准号:
    10598000
  • 财政年份:
    2020
  • 资助金额:
    $ 79.52万
  • 项目类别:
A Trans-Nordic Study of Extreme Major Depression
跨北欧的极度抑郁症研究
  • 批准号:
    10187656
  • 财政年份:
    2020
  • 资助金额:
    $ 79.52万
  • 项目类别:
A Trans-Nordic Study of Extreme Major Depression
跨北欧的极度抑郁症研究
  • 批准号:
    10034202
  • 财政年份:
    2020
  • 资助金额:
    $ 79.52万
  • 项目类别:
2/2 Genetics at an extreme: an efficient genomic study of individuals with clinically severe major depression receiving ECT
2/2 极端遗传学:对接受 ECT 的临床严重抑郁症患者进行有效的基因组研究
  • 批准号:
    10214484
  • 财政年份:
    2019
  • 资助金额:
    $ 79.52万
  • 项目类别:
2/2 Genetics at an extreme: an efficient genomic study of individuals with clinically severe major depression receiving ECT
2/2 极端遗传学:对接受 ECT 的临床严重抑郁症患者进行有效的基因组研究
  • 批准号:
    10021723
  • 财政年份:
    2019
  • 资助金额:
    $ 79.52万
  • 项目类别:
2/2 Genetics at an extreme: an efficient genomic study of individuals with clinically severe major depression receiving ECT
2/2 极端遗传学:对接受 ECT 的临床严重抑郁症患者进行有效的基因组研究
  • 批准号:
    10674837
  • 财政年份:
    2019
  • 资助金额:
    $ 79.52万
  • 项目类别:
2/2 Genetics at an extreme: an efficient genomic study of individuals with clinically severe major depression receiving ECT
2/2 极端遗传学:对接受 ECT 的临床严重抑郁症患者进行有效的基因组研究
  • 批准号:
    10455058
  • 财政年份:
    2019
  • 资助金额:
    $ 79.52万
  • 项目类别:
1/7 Psychiatric Genomics Consortium: Finding actionable variation
1/7 精神病学基因组联盟:寻找可行的变异
  • 批准号:
    9460671
  • 财政年份:
    2017
  • 资助金额:
    $ 79.52万
  • 项目类别:
1/7 Psychiatric Genomics Consortium: Finding actionable variation
1/7 精神病学基因组学联盟:寻找可行的变异
  • 批准号:
    9079743
  • 财政年份:
    2016
  • 资助金额:
    $ 79.52万
  • 项目类别:

相似海外基金

Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
  • 批准号:
    495182
  • 财政年份:
    2023
  • 资助金额:
    $ 79.52万
  • 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
  • 批准号:
    2601817
  • 财政年份:
    2021
  • 资助金额:
    $ 79.52万
  • 项目类别:
    Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
  • 批准号:
    2029039
  • 财政年份:
    2020
  • 资助金额:
    $ 79.52万
  • 项目类别:
    Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
  • 批准号:
    9888417
  • 财政年份:
    2019
  • 资助金额:
    $ 79.52万
  • 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
  • 批准号:
    17K11318
  • 财政年份:
    2017
  • 资助金额:
    $ 79.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9320090
  • 财政年份:
    2017
  • 资助金额:
    $ 79.52万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    10166936
  • 财政年份:
    2017
  • 资助金额:
    $ 79.52万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9761593
  • 财政年份:
    2017
  • 资助金额:
    $ 79.52万
  • 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
  • 批准号:
    BB/M50306X/1
  • 财政年份:
    2014
  • 资助金额:
    $ 79.52万
  • 项目类别:
    Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
  • 批准号:
    288272
  • 财政年份:
    2013
  • 资助金额:
    $ 79.52万
  • 项目类别:
    Miscellaneous Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了